Trials investigating the efficacy of an AI plus the TKI BMS-754807 or the IGF antibody MEDI-573 in ER+ breast cancer patients are completed and ongoing, respectively, but no results have been published. This evidence concerns the gene IGF1 and breast carcinoma.